TriSalus reaffirms 50% revenue growth target while advancing TriNav platform and product launches
Source: SeekingAlpha
2025-11-13 19:32:19 ET
More on TriSalus Life Sciences
- TriSalus Life Sciences, Inc. (TLSI) Q3 2025 Earnings Call Transcript
- TriSalus Life Sciences, Inc. (TLSI) Discusses Pressure-Enabled Drug Delivery and Advances in Uterine Fibroid Embolization Transcript
- TriSalus Life Sciences GAAP EPS of -$0.96 misses by $0.79, revenue of $11.6M misses by $0.16M
- Seeking Alpha’s Quant Rating on TriSalus Life Sciences
- Historical earnings data for TriSalus Life Sciences
Read the full article on Seeking Alpha
For further details see:
TriSalus reaffirms 50% revenue growth target while advancing TriNav platform and product launches
TriSalus Life Sciences Inc. Warrant
NASDAQ: TLSIW
TLSIW Trading
-1.27% G/L:
$1.56 Last:
1,306 Volume:
$1.58 Open:
TLSIW Latest News
TLSIW Stock Data
$218,310,730
36,224,125
N/A
18
N/A
Medical Equipment & Supplies
Healthcare
US
Westminster
